DE60123384D1 - Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert - Google Patents

Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert

Info

Publication number
DE60123384D1
DE60123384D1 DE60123384T DE60123384T DE60123384D1 DE 60123384 D1 DE60123384 D1 DE 60123384D1 DE 60123384 T DE60123384 T DE 60123384T DE 60123384 T DE60123384 T DE 60123384T DE 60123384 D1 DE60123384 D1 DE 60123384D1
Authority
DE
Germany
Prior art keywords
core
dosage form
faces
case
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60123384T
Other languages
English (en)
Other versions
DE60123384T2 (de
Inventor
Bret Berner
Jenny Louie-Helm
Gloria Gusler
N Shell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assertio Therapeutics Inc
Original Assignee
Depomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23983134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60123384(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Depomed Inc filed Critical Depomed Inc
Publication of DE60123384D1 publication Critical patent/DE60123384D1/de
Application granted granted Critical
Publication of DE60123384T2 publication Critical patent/DE60123384T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60123384T 2000-02-04 2001-01-30 Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert Expired - Fee Related DE60123384T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US498945 1983-05-27
US49894500A 2000-02-04 2000-02-04
PCT/US2001/003027 WO2001056544A2 (en) 2000-02-04 2001-01-30 Shell-and-core dosage form approaching zero-order drug release

Publications (2)

Publication Number Publication Date
DE60123384D1 true DE60123384D1 (de) 2006-11-09
DE60123384T2 DE60123384T2 (de) 2007-08-02

Family

ID=23983134

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60123384T Expired - Fee Related DE60123384T2 (de) 2000-02-04 2001-01-30 Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert

Country Status (13)

Country Link
US (6) US7736667B2 (de)
EP (1) EP1251832B1 (de)
JP (1) JP2003521507A (de)
AT (1) ATE340563T1 (de)
AU (1) AU767812B2 (de)
CA (1) CA2396782A1 (de)
DE (1) DE60123384T2 (de)
ES (1) ES2270982T3 (de)
HK (1) HK1050493A1 (de)
IL (2) IL150568A0 (de)
MX (1) MXPA02007254A (de)
PT (1) PT1251832E (de)
WO (1) WO2001056544A2 (de)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
CA2434169C (en) * 2001-01-12 2011-03-15 Sun Pharmaceutical Industries Limited Spaced drug delivery system
EP1435931A2 (de) * 2001-09-28 2004-07-14 Sun Pharmaceuticals Industries Ltd. Dosierform für die behandlung von diabetes mellitus
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
PT1476138E (pt) * 2002-02-21 2012-02-14 Valeant Internat Barbados Srl Formulações de libertação modificada de pelo menos uma forma de tramadol
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
EP1558081A4 (de) 2003-01-13 2006-06-14 Dynogen Pharmaceuticals Inc Verfahren zur behandlung von funktionalen darmerkrankungen
KR100772980B1 (ko) * 2004-04-01 2007-11-02 한미약품 주식회사 메트포르민의 경구투여용 서방성 제제
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
CN100459982C (zh) * 2004-08-30 2009-02-11 鲁南制药集团股份有限公司 去氧氟尿苷的分散片剂型
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
US20070021379A1 (en) 2005-07-11 2007-01-25 Pharmena North America Inc. Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities
US20070148227A1 (en) * 2005-12-27 2007-06-28 Hemant Joshi Physically/molecularly distributed and/or chemically bound medicaments in capsule shells
US8728521B2 (en) * 2005-12-27 2014-05-20 Hemant N. Joshi Physically/molecularly distributed and/or chemically bound medicaments in empty, hard capsule shells
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
WO2008073282A2 (en) * 2006-12-07 2008-06-19 Schering Corporation Ph sensitive matrix formulation
MX2009013494A (es) * 2007-06-11 2010-01-18 Procter & Gamble Agente benefico que contiene particulas de suministro.
CN101888828A (zh) * 2007-07-27 2010-11-17 蒂宝制药公司 脉冲胃滞留剂型
US8329750B2 (en) * 2008-02-11 2012-12-11 Depomed, Inc. Methods for treating vasomotor symptoms using GABA analogs in a gastric retentive dosage form
MX2010009990A (es) 2008-03-11 2010-12-15 Depomed Inc Formas de dosificación gástricas retentivas de liberación prolongada que comprenden combinaciones de un analgésico no opioide y un analgésico opioide.
US8372432B2 (en) * 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
PL2299984T3 (pl) 2008-05-15 2019-07-31 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
AU2009281752B2 (en) 2008-08-15 2016-11-17 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
WO2010129686A1 (en) 2009-05-05 2010-11-11 Vapogenix, Inc. Novel formulations of volatile anesthetics and methods of use for reducing inflammation
RU2012112552A (ru) * 2009-08-31 2013-10-10 Дипомед, Инк. Удерживаемые в желудке фармацевтические композиции для немедленного и продленного высвобождения ацетаминофена
US20110052700A1 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of levosulpiride
US20110104272A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine
US20110104273A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of phenylephrine
US20110135728A1 (en) * 2009-12-08 2011-06-09 Miller Jennifer L Gastric retentive pharmaceutical compositions for extended release of polypeptides
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
EP2389934A1 (de) * 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Tablettenformulierungen mit Pregabalin mit gesteuerter Freisetzung
CN103347517B (zh) 2010-08-11 2018-10-02 德雷克塞尔大学 治疗帕金森病中运动障碍的d3多巴胺受体激动剂
CA2850468C (en) 2010-09-28 2019-08-13 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
US8435993B2 (en) 2010-12-07 2013-05-07 Philadelphia Health And Education Corporation Methods of inhibiting metastasis from cancer
ES2753198T5 (es) 2010-12-16 2023-05-31 Amgen Europe Gmbh Formas farmacéuticas orales de liberación controlada de fármacos poco solubles y sus usos
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
SG10201510564PA (en) 2010-12-22 2016-01-28 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
ES2581323T3 (es) 2010-12-23 2016-09-05 Purdue Pharma Lp Formas de dosificación oral sólida resistentes a alteraciones
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
AU2012235878B2 (en) * 2011-03-25 2015-10-15 Purdue Pharma L.P. Controlled release pharmaceutical dosage forms
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
DE102011051653A1 (de) 2011-07-07 2013-01-10 Lts Lohmann Therapie-Systeme Ag Quellfähige Manteltablette
TW201700103A (zh) 2011-11-01 2017-01-01 西建公司 利用胞嘧啶核苷類似物之口服配方治療癌症的方法
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
KR20190007106A (ko) 2011-12-21 2019-01-21 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
WO2013091093A1 (en) * 2011-12-21 2013-06-27 Eatlittle, Inc. Pseudobezoar-based intraluminal gastrointestinal cleansing and biopsy
JP6397407B2 (ja) 2012-07-19 2018-09-26 ドレクセル ユニバーシティ 細胞タンパク質ホメオスタシスを調節するためのシグマ受容体リガンド
US9555012B2 (en) 2012-08-09 2017-01-31 Dynamis Therapeutics, Inc. Methods for maintaining or improving health, well-being and/or a physiological function in a subject
RS61101B1 (sr) 2013-01-07 2020-12-31 Univ Pennsylvania Preparati i postupci za lečenje kožnog limfoma t-ćelija
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
EP3878445A3 (de) 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosat-formulierungen, verfahren zur verwendung davon und kombinationen damit
ES2769893T3 (es) 2013-07-02 2020-06-29 Ecoplanet Env Llc Formulaciones de compuestos orgánicos volátiles que tienen actividad antimicrobiana
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
EP3074049B1 (de) 2013-11-26 2020-05-06 Yale University Neuartige zellenpenetrierende zusammensetzungen und verfahren zur verwendung davon
WO2015089049A1 (en) 2013-12-09 2015-06-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
EP3128996B1 (de) 2014-04-07 2021-06-02 University of Rochester Neuartige 7-dehydrocholesterinderivate und verfahren damit
EP3148514B1 (de) 2014-06-02 2024-04-17 Clexio Biosciences Ltd. Expandierbare gastroretentive darreichungsform
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
AU2015284425B2 (en) 2014-07-01 2021-04-01 Probi USA, Inc. Bi-layer dual release probiotic tablets
CA2968215A1 (en) 2014-08-20 2016-02-25 Yale University Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
AU2015305449B2 (en) 2014-08-22 2021-05-06 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
WO2016033295A1 (en) * 2014-08-27 2016-03-03 The Regents Of The University Of Colorado, A Body Corporate Multilayer polymeric matrix based medical devices
EP3258916A1 (de) 2015-02-20 2017-12-27 Osmotica Kereskedelmi ES Szolgaltato KFT Oralen darreichungsform mit kontrollierter freisetzung aus gaba-rezeptor-agonisten mit verbesserter pharmakokinetik
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10597368B2 (en) 2015-05-08 2020-03-24 Brown University Syringolin analogues and methods of making and using same
JP6995627B2 (ja) 2015-05-19 2022-02-04 イエール ユニバーシティ 病的石灰化状態を治療するための組成物およびそれを使用する方法
US10829440B2 (en) 2015-06-12 2020-11-10 Brown University Antibacterial compounds and methods of making and using same
WO2016209061A1 (ko) * 2015-06-26 2016-12-29 한국유나이티드제약 주식회사 모사프리드와 라베프라졸의 복합제제
CN107708701A (zh) 2015-06-30 2018-02-16 纽拉德有限公司 新颖呼吸控制调节化合物以及其制备和使用方法
US20180242575A1 (en) * 2015-08-18 2018-08-30 Basf Se Agrochemical microcapsules with a shell of polyvinylalcohol and polyoxazoline
WO2017066599A1 (en) 2015-10-15 2017-04-20 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
AU2016340098B2 (en) 2015-10-15 2022-06-02 Celgene Corporation Combination therapy for treating malignancies
PL3362066T3 (pl) 2015-10-15 2022-05-02 Les Laboratoires Servier Terapia skojarzona do leczenia nowotworów złośliwych
WO2017075145A1 (en) 2015-10-28 2017-05-04 Yale University Quinoline amides and methods of using same
WO2017083348A1 (en) 2015-11-11 2017-05-18 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
EP4079322A1 (de) 2015-11-20 2022-10-26 Yale University Zusammensetzungen zur behandlung von ektopischen verkalkungsstörungen und verfahren damit
IL299563A (en) 2015-12-04 2023-02-01 Agios Pharmaceuticals Inc Methods for the treatment of acute myeloid leukemia characterized by the presence of a mutant allele of IDH2 and the absence of a mutant allele of NRAS
US10137130B2 (en) 2016-02-26 2018-11-27 Celgene Corporation Methods of treatment of malignancies
US20190119364A1 (en) 2016-04-29 2019-04-25 The Regents Of The University Of Colorado, A Body Corporate Compounds and compositions useful for treating metabolic syndrome, and methods using same
WO2018026764A1 (en) 2016-08-01 2018-02-08 University Of Rochester Nanoparticles for controlled release of anti-biofilm agents and methods of use
EP3493809B1 (de) 2016-08-03 2023-08-23 Celgene Corporation Enasidenib zur behandlung von myelodysplastischem syndrom
AU2017306549A1 (en) 2016-08-05 2019-02-21 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
EP3506983B1 (de) 2016-09-01 2021-08-25 Mebias Discovery, Inc. Substituierte harnstoff-derivate zur behandlung von schmerz
CA3040919A1 (en) 2016-11-07 2018-05-11 Arbutus Biopharma Corporation Substituted pyridinone-containing tricyclic compounds, and methods using same
IL266377B2 (en) 2016-12-02 2023-10-01 Clexio Biosciences Ltd Stomach retention system
EP4219486A1 (de) 2017-01-19 2023-08-02 Temple University of the Commonwealth System of Higher Education Verbrückte bicycloalkyl-substituierte aminothizole und verfahren zu ihrer verwendung
MA49014A (fr) 2017-03-21 2020-02-05 Arbutus Biopharma Corp Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
EP3612184A4 (de) 2017-04-17 2021-01-20 Yale University Verbindungen, zusammensetzungen und verfahren zur behandlung oder prävention von akuten lungenverletzungen
US11229653B2 (en) 2017-05-05 2022-01-25 Celgene Corporation Methods of treatment of myeloproliferative neoplasm
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
CA3031412C (en) 2017-06-16 2020-08-11 Kashiv Pharma Llc Gastroretentive dosage forms for sustained drug delivery
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
CA3071345A1 (en) 2017-07-28 2019-01-31 Yale University Anticancer drugs and methods of making and using same
CA3074017A1 (en) 2017-09-08 2019-03-14 The Regents Of The University Of Colorado, A Body Corporate Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers
EP3716985A1 (de) 2017-11-27 2020-10-07 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Verbindungen, zusammensetzungen und verfahren zur behandlung und/oder prävention von parodontopathie
US11547839B2 (en) 2017-12-04 2023-01-10 Clexio Biosciences Ltd. Long acting gastric residence system
WO2019125184A1 (en) 2017-12-19 2019-06-27 Auckland Uniservices Limited Use of biomarker in cancer therapy
CA3089236A1 (en) 2018-01-24 2019-08-01 The Rockefeller University Antibacterial compounds, compositions thereof, and methods using same
EA202092691A1 (ru) 2018-05-29 2021-04-21 Церси Терапьютикс, Инк. Соединения для устранения боли, композиции, содержащие их, и способы их применения
EP3609472B1 (de) 2018-06-18 2020-12-30 Kashiv Specialty Pharmaceuticals, LLC Retard-zusammensetzungen mit pyridostigmin
KR102651652B1 (ko) 2018-10-11 2024-03-26 사니핏 테라퓨틱스 에스.에이. 이소성 석회화의 치료를 위한 이노시톨 포스페이트
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
WO2020092894A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
KR20210148078A (ko) 2019-01-30 2021-12-07 사니핏 테라퓨틱스 에스.에이. 조직 관류 증가에 사용하기 위한 이노시톨 포스페이트 화합물
US20200246317A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
WO2020159565A1 (en) 2019-02-01 2020-08-06 Cersci Therapeutics, Inc. Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
US11471508B2 (en) 2019-05-09 2022-10-18 The Feinstein Institutes For Medical Research HMGB1 antagonist treatment of diabetic peripheral neuropathy
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents
EP3818983A1 (de) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol-phosphat-verbindungen zur verwendung in der behandlung, progressionshemmung oder verhinderung von kardiovaskulärer verkalkung
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
CA3181983A1 (en) 2020-06-09 2021-12-16 Zhiliang Cheng Soluble enpp1 or enpp3 proteins and uses thereof
CN112034057B (zh) * 2020-08-16 2022-04-01 江苏正大清江制药有限公司 一种测定头孢呋辛酯原料中高分子聚合物的方法
EP4015494A1 (de) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Verfahren zur herstellung von löslichen salzen von inositolphosphaten
EP4036097A1 (de) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6-substituierte derivatverbindungen
WO2024023359A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2024023360A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip5 substituted compounds
WO2024052895A1 (en) 2022-09-06 2024-03-14 Hadasit Medical Research Services And Development Ltd Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
ZA722664B (en) 1971-05-18 1973-01-31 Smith Kline French Lab Lyered bolus for animal husbandry providing for immediate and sustained release of medicament
CH582002A5 (de) * 1972-06-09 1976-11-30 Purdue Research Foundation
US4088798A (en) 1975-11-11 1978-05-09 Sandoz, Inc. Methods for the preparation of controlled gastric residence time medicament formulations
US4207890A (en) 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
JPS58134019A (ja) 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
US4629620A (en) 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4892742A (en) 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4867969A (en) 1986-02-07 1989-09-19 Alza Corporation Hydrogel formulation for administering non-steroidal drugs
JPS62195323A (ja) 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4816264A (en) 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
US4789549A (en) 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
US4891223A (en) 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US5190760A (en) * 1989-07-08 1993-03-02 Coopers Animal Health Limited Solid pharmaceutical composition
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
AT397345B (de) * 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
ATE118345T1 (de) 1990-08-07 1995-03-15 Pfizer Verwendung von interfacial polymerisierten membranen in abgabevorrichtungen.
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
US5512299A (en) 1992-03-30 1996-04-30 Alza Corporation Method of treating oral inflammatory disease
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
US5391378A (en) 1993-02-22 1995-02-21 Elizabeth-Hata International, Inc. Two-part medicinal tablet and method of manufacture
WO1995003033A1 (en) 1993-07-22 1995-02-02 Pfizer Inc. Osmotic devices having vapor-permeable coatings
US5415688A (en) 1993-09-20 1995-05-16 Ameron, Inc. Water-borne polysiloxane/polysilicate binder
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
IT1265240B1 (it) 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
HU213407B (en) 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5458888A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
MY113429A (en) 1995-02-28 2002-02-28 Univ Temple Controlled release tablet containing swellable polyethylene oxide
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5736159A (en) 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5783212A (en) 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US6149940A (en) * 1996-08-29 2000-11-21 Synthelabo Tablet with controlled release of alfuzosine chlorhydrate
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
NZ336691A (en) 1997-01-14 2000-05-26 Lohmann Therapie Syst Lts Expandable gastro-retentive therapeutic system with controlled active substance release in the gastro-intestinal tract
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
EP0998271B3 (de) * 1997-06-06 2014-10-29 Depomed, Inc. Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
ATE285226T1 (de) * 1997-08-11 2005-01-15 Alza Corp Gastrische zurückhalteform zur verlängerten freisetzung eines wirkstoffs
US5916595A (en) 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
CA2220038A1 (en) * 1998-01-05 1999-07-05 Amina Odidi Device for the delivery of high dose pharmaceutical, neutraceutical, agricultural, biological, and chemical substances
EA003101B1 (ru) * 1998-03-19 2002-12-26 Бристол-Майерз Сквибб Компани Двухфазная система доставки с регулируемым высвобождением для фармацевтических средств с высокой растворимостью и способ лечения диабета с помощью этой системы
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data

Also Published As

Publication number Publication date
IL150568A0 (en) 2003-02-12
US8043630B2 (en) 2011-10-25
CA2396782A1 (en) 2001-08-09
MXPA02007254A (es) 2002-12-09
HK1050493A1 (en) 2003-06-27
US20150182541A1 (en) 2015-07-02
ES2270982T3 (es) 2007-04-16
WO2001056544A3 (en) 2002-05-02
US9597338B2 (en) 2017-03-21
US20030104062A1 (en) 2003-06-05
EP1251832A2 (de) 2002-10-30
US20110236485A1 (en) 2011-09-29
US20100272808A1 (en) 2010-10-28
PT1251832E (pt) 2007-01-31
ATE340563T1 (de) 2006-10-15
WO2001056544A2 (en) 2001-08-09
US8945619B2 (en) 2015-02-03
IL150568A (en) 2007-12-03
US8329215B2 (en) 2012-12-11
US7736667B2 (en) 2010-06-15
AU767812B2 (en) 2003-11-27
EP1251832B1 (de) 2006-09-27
AU3466101A (en) 2001-08-14
DE60123384T2 (de) 2007-08-02
US20130164377A1 (en) 2013-06-27
US20170172930A1 (en) 2017-06-22
JP2003521507A (ja) 2003-07-15

Similar Documents

Publication Publication Date Title
DE60123384D1 (de) Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
NO20014859L (no) Raskt dispergerbare doseringsformer inneholdende fiskegelatin
IL153464A0 (en) A controlled release oral drug dosage form
ATE260646T1 (de) Schnell zerfallende orale dosierungsform
TR200200561T2 (tr) Mesalazin içeren ve vücut içinde kontrollü bir şekilde salgılanabilen ağızdan alınan farmasötik bileşimler
ATE211907T1 (de) Osmotisches arzneimittelfreisetzungssystem
ID29837A (id) Formulasi dosis oral yang mencair seketika
DE50109662D1 (de) Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
BR0112054A (pt) Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico
CY1105908T1 (el) Στοματικως αποσαθρουμενα δισκια που πepιλαμβανουν βενζιμιδαζολιο
BR0107565A (pt) Formas de dosagem de benzimidazol substituìdo e método de emprego das mesmas
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
AP2003002763A0 (en) Controlled release formulations for oral administration
ATE247953T1 (de) Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.
DK1292303T3 (da) Stabil farmaceutisk formulering omfattende torsemidmodifikation II
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
DZ3103A1 (fr) Nouvelles pyrazolo Ä4,3-EÜdiazépines substituées, compositions pharmaceutiques les contenant, utili sation à titre de médicament et procédés pour leurs préparation.
WO2003037296A3 (en) Methods and dosage forms for improving the bioavailability of therapeutic agents
TR200301552A1 (tr) Rofekoksib' in yeni oral farmakolojik formülasyonları.
TH46047A (th) สารผสมซีลีคอกซิบ (celcecoxib)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee